Abstract:Aim: Cancer as a complex disease poses significant challenges for both diagnosis and treatment. Researchers have been exploring various avenues to find effective therapeutic strategies, with a particular emphasis on cellular signaling pathways and immunotherapy. One such pathway that has recently been suggested is the PD-1/PD-L1 pathway, which is an immune checkpoint signaling system that plays an important role in regulating the immune system and maintaining tissue homeostasis. Cancer cells exploit this pathway by producing PD-L1, which attaches to PD-1 on T cells, thus inhibiting immune responses and enabling the cancer cells to escape detection by the immune system. This study aimed to evaluate the role of the PD-1/PD-L1 pathway in cancer pathogenesis and treatment. Method: This study was performed based on the principles of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). All in vitro , in vivo , and clinical studies that were published in English have been considered during a thorough search of the Scopus, Web of Science, and PubMed databases without date restriction until March 2024. Results: According to the studies reviewed, the PD-1/PD-L1 signaling axis suggests promising therapeutic effects on various types of cancers such as non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, squamous cell carcinoma, and colorectal cancer, among others. Additionally, research suggests that immune checkpoint inhibitors that block PD1/PD-L1, such as pembrolizumab, atezolizumab, nivolumab, durvalumab, cemiplimab, avelumab, etc. , can effectively prevent tumor cells from escaping the immune system. Moreover, there might be a possible interaction between microbiome, obesity, etc. on immune mechanisms and on the immune checkpoint inhibitors (ICIs). Conclusion: Although we have gained considerable knowledge about ICIs, we are still facing challenges in effectively prescribing the appropriate ICIs for individual patients. This is largely due to the complex interactions between different intracellular pathways, which need to be thoroughly studied. To resolve this issue, it is necessary to conduct more reliable clinical trials that can produce a scientific consensus.

PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy

The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

PD-1/PD-L1 pathway: current researches in cancer.

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment

PD-1 regulation in immune homeostasis and immunotherapy

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

A snapshot of the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

Application of PD-1 Blockade in Cancer Immunotherapy

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway.

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Generation, secretion and degradation of cancer immunotherapy target PD-L1

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.

Biomarkers of response to PD-1/PD-L1 inhibition